Showing results (1-10 of 640) with videos related to
Sort By:
Pageof 64
Klinische Wochenschrift|March 1, 1983
Interdigestive motilin secretion and gallstone diseaseR Klapdor, E HammerResearch in Experimental Medicine. Zeitschrift Fur Die Gesamte Experimentelle Medizin Einschliesslich Experimenteller Chirurgie|October 29, 1976
Improvement of biliary excretion of ioglycamide by pretreatment with phenobarbitalR KlapdorLangenbecks Archiv Fur Chirurgie. Supplement II, Verhandlungen Der Deutschen Gesellschaft Fur Chirurgie. Deutsche Gesellschaft Fur Chirurgie. Kongress|January 1, 1990
[Is there an advantage to neo- or adjuvant chemotherapy in pancreatic cancer?]R KlapdorResearch in Experimental Medicine. Zeitschrift Fur Die Gesamte Experimentelle Medizin Einschliesslich Experimenteller Chirurgie|January 1, 1982
Release of gastric inhibitory polypeptide (GIP) and gastrin after a test meal with a low glucose load in patients after BII resection, proximal duodenopancreatectomy (PDP) and jejunoileal bypassR KlapdorHepato-Gastroenterology|August 1, 1981
On the kinetics of glycocholate uptake and excretion by the normal and diseased liver in manR KlapdorActa Hepato-Gastroenterologica|June 1, 1978
Necessity of a 3-compartmental model for analyzing the distribution and excretion kinetics of i.v. injected bile acids in manR KlapdorRofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin|August 1, 1978
[Dose-effects of the contrast medium Iotroxinate on biliary excretion of contrast media during infusion cholegraphy (author's transl)]R KlapdorActa Hepato-Gastroenterologica|February 1, 1979
Further evidence for the superiority of a 3-compartmental model for distribution analyses of i.v. injected bile acids in men: studies in patients with liver diseasesR KlapdorArzneimittel-Forschung|January 1, 1978
Inhibition of bile salt excretion and bile flow by spasmolytic drugs. An additional therapeutic effect in the treatment of biliary colics?R Klapdor, H SepehrAnticancer Research|May 1, 2001
Irinotecan(Campto R): efficacy as third/forth line therapy in advanced pancreatic cancerR Klapdor, C FennerPageof 64